Page last updated: 2024-12-05
3-chloro-1-propanol
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
3-chloro-1-propanol: an inhibitor of triosephosphate isomerase and glyceraldehyde 3-phosphate dehydrogenase [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 12313 |
| CHEMBL ID | 1230102 |
| MeSH ID | M0286202 |
Synonyms (61)
| Synonym |
|---|
| 3-chloropropanol-1 |
| unii-148011u61g |
| 4-01-00-01441 (beilstein handbook reference) |
| 3-chlorpropan-1-ol |
| 3-chloropropanol-1 [un2849] [poison] |
| 148011u61g , |
| CHEMBL1230102 |
| 3-chloro-1-propanol |
| nsc-60190 |
| nsc60190 |
| 1-chloro-3-hydroxypropane |
| 3-chloropropanol |
| trimethylene chlorohydrin |
| 1-propanol, 3-chloro- |
| 627-30-5 |
| 3-chloropropan-1-ol |
| inchi=1/c3h7clo/c4-2-1-3-5/h5h,1-3h |
| 3-chloro-l-propanol |
| brn 0773655 |
| nsc 60190 |
| 3-chlorpropan-1-ol [german] |
| ccris 4767 |
| ai3-61821 |
| un2849 |
| einecs 210-992-9 |
| 3-choro-1-propanol |
| 3-chloro-1-propanol, 98% |
| 3CL , |
| AKOS000121342 |
| 3-chloranylpropan-1-ol |
| A833956 |
| 28064-81-5 |
| propanol, chloro- |
| 3-chloro-propan-1-ol |
| 1-chloro-3-hydroxypropane, 3-chloro-1-propanol, trimethylene chlorohydrin |
| FT-0615298 |
| FT-0623694 |
| chloro-1-propanol, 3- |
| 3-chloro-1 propanol |
| 1-chloro-3-propanol |
| 3-chloro-propanol |
| trimethylene chlorohydrine |
| 3-chloropropane-1-ol |
| 3-chloro-1-hydroxypropane |
| propanol, 3-chloro- |
| un 2849 |
| dtxsid9024809 , |
| tox21_303962 |
| cas-627-30-5 |
| dtxcid604809 |
| NCGC00357193-01 |
| Q-200369 |
| Q-200368 |
| STR03655 |
| F0001-1685 |
| mfcd00002943 |
| AMY9478 |
| E78849 |
| Q27251597 |
| 3-chloro-1-propanol 100 microg/ml in acetonitrile |
| EN300-22342 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (1)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 2.4337 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 37.96
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (37.96) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||